Travere Therapeutics, Inc. · NASDAQ:TVTX
Travere Therapeutics — Corporate Update (June 2026)
19 slides from Travere Therapeutics's corporate update, Jun 2, 2026
Slide 1: Travere Enters Into Licensing Agreement with Everest Medicines for Civorebrutinib
Travere Enters Into Licensing Agreement with Everest Medicines for Civorebrutinib (EVER001) June 2, 2026
Slide 2: Today's Speakers
Today’s Speakers Eric Dube, Ph.D. Jula Inrig, M.D. President and Chief Executive Chief Medical Officer Officer 2
Slide 3: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, including but not limited to: statements regarding our products and products in development as potential best-in-class treatments or treatment standards, and potential future indications; statements and expectations re
Slide 4: Civorebrutinib: Clear Strategic Fit to Expand Travere's Leadership in Rare Kidney Diseases
Civorebrutinib: Clear Strategic Fit to Expand Travere’s Leadership in Rare Kidney Diseases 1 2 3 Strengthens Travere’s Pipeline-in-a-Product Potential Best-in-Class Pipeline Potential Profile Expands Travere’s pipeline of The only covalent reversible BTK B-cell acting mechanism provides potential be
Slide 5: Key Transaction Terms and Financial Overview
Key Transaction Terms and Financial Overview • Travere acquires exclusive rights outside of China and certain countries in East and Southeast Transaction Asia to develop and commercialize civorebrutinib (EVER001) and will collaborate with Everest Summary Medicines on U.S. and global development plan
Slide 6: Civorebrutinib is a Potent Covalent Reversible BTK Inhibitor
Civorebrutinib is a Potent Covalent Reversible BTK Inhibitor with Potential Across Several Immune-Mediated Rare Kidney Indications Civorebrutinib is a potential best-in-class BTK inhibitor differentiated by oral administration, with rapid onset of action, high selectivity, strong potency, and a pote
Slide 7: Significant Diagnosed Patient Population Across Potential Rare Kidney Disease Opportunities
Diagnosed Prevalence Cases Across Immune-Mediated Rare Kidney Diseases >20k Significant Diagnosed Immune- mediated Patient Population FSGS2 Across Potential Rare Kidney Disease Opportunities >130k >20k >90k diagnosed patients MCD3 pMN1 across multiple indications Mechanistic rationale supports furth
Slide 8: Primary Membranous Nephropathy is Among Most Prevalent Nephrotic Syndromes with No Approved Treatment Options
Primary Membranous Nephropathy is Among Most Prevalent Nephrotic Syndromes with No Approved Treatment Options ~25% ~30% ~30-40% High Risk Relapse Refractory to standard of disease progression1 after remission2 of care (SOC)3 Despite investigation of other targeted therapies (CD20, BAFF/APRIL, CD38),
Slide 9: Primary Membranous Nephropathy Represents Significant Patient and Community Burden
Primary Membranous Nephropathy Represents Significant Patient and Community Burden Symptoms of pMN ~60-70% of patients present with nephrotic syndrome1,2 “Brain Fog” Ophthalmic problems ~60% Fatigue of patients presenting with sub nephrotic- range proteinuria will progress to full nephrotic syndrome
Slide 10: BTK Inhibitors Target Multiple Key Nodes in the Pathogenesis of Primary Membranous Nephropathy
BTK Inhibitors Target Multiple Key Nodes in the Pathogenesis of Primary Membranous Nephropathy BTK inhibitors suppress B-cell signaling, BTK inhibitors provide functional B-cell Oral BTK inhibitors may allow for more reducing B-cell activation and modulation without broad b-cell or rapid recovery of
Slide 11: Phase 1b/2a Study of Civorebrutinib in Patients with pMN with Positive Anti-PLA2R Autoantibody
Phase 1b/2a Study of Civorebrutinib in Patients with pMN with Positive Anti-PLA2R Autoantibody Part A Part B Low Dose: civorebrutinib (EVER001) 100mg QD×4W→ Follow-up Extended Follow-up Period 100mg BID×32W（N=13） Data from at least 8 pts 36 weeks treatment 16 weeks Up to Week 104 dosed for 10 days i
Slide 12: Phase 1/2 Proof of Concept: Rapid and Sustained Reductions in Key Disease Biomarkers
Phase 1/2 Proof of Concept: Civorebrutinib Demonstrated Rapid and Sustained Reductions in Key Disease Biomarkers Percent Change in Anti-PLA2R from Baseline (FAS) 0% Geometric LS Mean of Percent Change from Off treatment -20% ~90% ~90% -40% Baseline, % -62.2% -60% reduction in reduction in anti-PLA2R
Slide 13: Phase 1/2 Proof of Concept: Rapid and Sustained Reductions in Key Disease Biomarkers
Phase 1/2 Proof of Concept: Civorebrutinib Demonstrated Rapid and Sustained Reductions in Key Disease Biomarkers 40% Percent Change in 24h Proteinuria from Baseline (FAS) Geometric LS Mean of Percent Change from Off treatment 20% ~80% ~80% 0% Baseline, % -24.5% -20% -29.9% reduction in reduction in
Slide 14: Favorable Safety and Tolerability Profile
Favorable Safety and Tolerability Profile No clinically meaningful AEs typically associated with BTK inhibitors, such as neutropenia, hemorrhage, cardiac arrythmia Cohort 1 (N=13) Cohort 2 (N=18) Category of AEs, n (%) 100mg QD→ Total (N=31) 200mg BID 100mg BID Treatment emergent AE (TEAE) 12 (92.3)
Slide 15: Civorebrutinib is a Viable Candidate to Address Key Gaps in pMN Treatment
With the Potential for Rapid, Controllable Immune Modulation, Civorebrutinib is a Viable Candidate to Address Key Gaps in pMN Treatment Rapid and sustained reductions in key disease biomarkers seen in Phase 1/2 study (anti-PLA2R and proteinuria) Oral administration Convenient patient-friendly option
Slide 16: BTK Inhibitor Mechanism Has Promising Potential in Several Rare Kidney Diseases, including FSGS and MCD
BTK Inhibitor Mechanism Has Promising Potential in Several Rare Kidney Diseases, including Immune-Mediated FSGS and MCD BTK plays a functional role in immune cell types involved in FSGS pathology BTKi's have a potential role in FSGS with immune cell involvement BTKi’s target overactivation in the im
Slide 17: Building on Travere's Leadership and Track Record of Execution in Rare Nephrology
Clinical infrastructure that has completed some of the largest rare kidney trials to-date to support regulatory approvals Building on Travere’s Leadership and Track Record of Execution Mission to identify, develop, and deliver Regulatory in Rare Nephrology life-changing therapies for people living w
Slide 18: Expanding the Pipeline of Potential Best-in-Class Programs Targeting Rare Kidney and Metabolic Diseases
Expanding the Pipeline of Potential Best-in-Class Programs Targeting Rare Kidney and Metabolic Diseases PROGRAM THERAPEUTIC AREA PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVED COMMERCIAL FILSPARI® IgAN (sparsentan)1 FILSPARI® FSGS (sparsentan)2 Thiola EC® and Cystinuria Thiola® (tiopronin) Pegtibatina
Slide 19: Inc.
© 2026 2025 Travere Therapeutics, Inc. Inc.